The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162. doi:10.1097/jto.0000000000000033
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl4):iv192–iv237. doi:10.1093/annonc/mdy275
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Non-small cell lung cancer (Version: 1.2023). Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed December 27, 2022.
   Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci. 2022;23(7):3636. doi:10.3390/ijms23073636
   PubMed Web of Science ®Google Scholar
• Mortaz E, Alipoor SD, Adcock IM, Mumby S, Koenderman L. Update on neutrophil function in severe inflammation. Front Immunol. 2018;9:2171. doi:10.3389/fimmu.2018.02171
   PubMed Web of Science ®Google Scholar
• Lee MJ, Park SD, Kwon SW, et al. Relation between neutrophil-to-lymphocyte ratio and index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2016;118(9):1323–1328. doi:10.1016/j.amjcard.2016.07.072
   PubMed Web of Science ®Google Scholar
• Lowsby R, Gomes C, Jarman I, et al. Neutrophil to lymphocyte count ratio as an early indicator of blood stream infection in the emergency department. Emerg Med J. 2015;32(7):531–534. doi:10.1136/emermed-2014-204071
   PubMed Web of Science ®Google Scholar
• Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5–14.
   PubMedGoogle Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju124
   PubMedGoogle Scholar
• Bryant AK, Sankar K, Strohbehn GW, et al. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. Lung Cancer. 2022;163:35–41. doi:10.1016/j.lungcan.2021.11.021
   PubMed Web of Science ®Google Scholar
• Tang M, Gao X, Sun H, et al. Neutrophil-lymphocyte ratio as a prognostic parameter in NSCLC patients receiving EGFR-TKIs: a systematic review and meta-analysis. J Oncol. 2021;2021:6688346. doi:10.1155/2021/6688346
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhan P, Lv Y, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. Transl Lung Cancer Res. 2019;8(3):214–226. doi:10.21037/tlcr.2019.06.10
   PubMed Web of Science ®Google Scholar
• Xu C, Yao X, Li T, et al. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant non-small cell lung cancer. Transl Cancer Res. 2020;9(4):2875–2883. doi:10.21037/tcr.2020.02.28
   PubMed Web of Science ®Google Scholar
• Yun NK, Rouhani SJ, Bestvina CM, et al. Neutrophil-to-lymphocyte ratio is a predictive biomarker in patients with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitor (TKI) therapy. Cancers. 2021;13(6):1426. doi:10.3390/cancers13061426
   PubMed Web of Science ®Google Scholar
• Park JY, Jang SH, Lee CY, et al. Pretreatment neutrophil-to-lymphocyte ratio and smoking history as prognostic factors in advanced non-small cell lung cancer patients treated with osimertinib. Tuberc Respir Dis. 2022;85(2):155–164. doi:10.4046/trd.2021.0139
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa1612674
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Hsu KH, Ho CC, Hsia TC, et al. Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. PLoS One. 2015;10(3):e0120852. doi:10.1371/journal.pone.0120852
   PubMed Web of Science ®Google Scholar
• Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the Roche cobas(R) EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017;17(3):209–215. doi:10.1080/14737159.2017.1288568
   PubMed Web of Science ®Google Scholar
• Bowen RC, Little NAB, Harmer JR, et al. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(19):32171–32189. doi:10.18632/oncotarget.16291
   PubMedGoogle Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.11058
   PubMed Web of Science ®Google Scholar
• Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–1356. doi:10.1038/s41591-021-01450-2
   PubMed Web of Science ®Google Scholar
• Gray JE, Okamoto I, Sriuranpong V, et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res. 2019;25(22):6644–6652. doi:10.1158/1078-0432.Ccr-19-1126
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa1913662
   PubMed Web of Science ®Google Scholar
• Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159–2167. doi:10.1182/blood-2018-11-844548
   PubMed Web of Science ®Google Scholar
• Grieshaber-Bouyer R, Radtke FA, Cunin P, et al. The neutrotime transcriptional signature defines a single continuum of neutrophils across biological compartments. Nat Commun. 2021;12(1):2856. doi:10.1038/s41467-021-22973-9
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des. 2009;15(16):1879–1892. doi:10.2174/138161209788453211
   PubMed Web of Science ®Google Scholar
• Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474–488. doi:10.4149/bll_2021_078
   PubMed Web of Science ®Google Scholar
• O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024–2036. doi:10.1097/jto.0b013e3181f387e4
   PubMed Web of Science ®Google Scholar
• Wang Q, Shi Q, Lu J, Wang Z, Hou J. Causal relationships between inflammatory factors and multiple myeloma: a bidirectional Mendelian randomization study. Int J Cancer. 2022;151(10):1750–1759. doi:10.1002/ijc.34214
   PubMed Web of Science ®Google Scholar
• Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14:117. doi:10.1186/1471-2407-14-117
   PubMed Web of Science ®Google Scholar
• Ma SJ, Yu H, Khan M, et al. Evaluation of optimal threshold of neutrophil-lymphocyte ratio and its association with survival outcomes among patients with head and neck cancer. JAMA Netw Open. 2022;5(4):e227567. doi:10.1001/jamanetworkopen.2022.7567
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen K, Xiao X, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer. 2016;16:320. doi:10.1186/s12885-016-2352-8
   PubMed Web of Science ®Google Scholar
• Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–184. doi:10.1002/jso.20329
   PubMed Web of Science ®Google Scholar